November 28 news, there are seven positive may affect tomorrow's stock market, specifically:
Tonghua Dongbao: multi-specification products to win the bid for insulin collection
Tonghua Dongbao (600867) announced on the evening of the 26th, the company's human insulin injection, protamine human insulin injection, protamine human insulin mixed injection, glargine insulin injection and Mendong insulin injection are intended to win the bid for the sixth batch of national centralized drug procurement (insulin special). All the insulin products of the company participated in the bidding, and the whole line of products were proposed to win the bid with Class B. The company intends to win the bid for products with a total sales of 2.05 billion yuan in the first three quarters of 2021, accounting for 83.54% of the company's revenue. The price of the products to be selected by the company has decreased to a certain extent compared with the original price, but there is an agreed guarantee of the basic quantity of procurement. At the same time, the above category B winning products will also receive an increase of 80% of the procurement demand for category D selected products in the first year. This collection will help the company to further expand the sales of related products, especially insulin analogues, accelerate product access and increase market share.
Beijing Kerry: the controller proposes 100 million to 200 million yuan to buy back shares
Beijing Kerry (002350) 26 evening announcement, the company's actual controller, chairman Fu Xiaodong proposed to buy back the company's shares. The share buyback plan is as follows: the total capital of the company to buy back shares in the way of centralized bidding transaction is not less than 100 million yuan and not more than 200 million yuan; the repurchase price is not more than 11.74 yuan per share, and the repurchase shares are used for the later implementation of equity incentive plan or employee stock ownership plan. In addition, the company plans to invest 137.7 million yuan in Beijing Wenli Technology Co., Ltd. through equity transfer and capital increase to hold a 63.4% stake in Beijing Wenli. This investment will further improve the layout of the company's hydrogen energy industry chain.
Zhongheng Electric: sign a contract with BABA for the purchase and supply of 800 million yuan of power equipment
Zhongheng Electric (002364) announced on the evening of November 26th that recently, the company and BABA (China) Co., Ltd. signed the "BABA data Center 2021 Panama Power supply Framework Project Purchasing and supply Framework contract" for the winning project. The total contract amount is about 800 million yuan, accounting for 56% of the company's operating income in 2020.
Shen Sangda A: to invest in Digital Guangdong Co., Ltd together with the real controller.
Shen Sangda A (000032) announced on the evening of the 28th that the company, together with the controller China Electronics and Guangdong Guangdong Yueke Financial Group, intends to invest in Digital Guangdong Network Construction Co., Ltd. (hereinafter referred to as "Digital Guangdong Network Construction Co., Ltd."). In the end, it can achieve the goal that China Electronics, the company or the respective designated parties of both parties hold not less than 51% of the shares in a wide range of companies, and Yueke Financial Group holds no less than 1% and no more than 5% of the shares. Jiguang Company is the construction and operation center of digital government in Guangdong Province, which provides technical support for the reform and construction of digital government in Guangdong Province, and promotes the construction of information infrastructure such as government cloud and government network in the province as a whole. This investment will greatly enhance the company's industry influence in the field of digital government.
Ganli Pharmaceutical Co., Ltd.: 6 products and related regulations are planned to select insulin for special collection.
Ganli Pharmaceutical (603087) announced on the evening of November 28th, the company's products protamine human insulin mixed injection (30R), preserved insulin injection, asparagus insulin injection, glargine insulin injection, protamine zinc recombinant Laipun insulin mixed injection (25R) and Mendong insulin 30 injection are planned to be selected in the sixth batch of national organization drug centralized volume procurement (insulin special). The total sales of the six products and related regulations mentioned above are 3.207 billion yuan in 2020, accounting for 95.38% of the company's operating income for the year.
Dewey: the proposed share buyback will be used to implement the equity incentive plan.
Dewey (688377) announced on the evening of November 28th that Zhang Li, the chairman and controller of the company, proposed that the company should buy back shares to implement the equity incentive plan. The total repurchase capital shall be no less than 30 million yuan and not more than 60 million yuan, and the repurchase price shall not exceed 22 yuan per share. It is estimated that 1.3636 million to 2.7273 million shares can be repurchased. Dewey also disclosed the draft restricted stock incentive plan for 2021, which shows that the company intends to grant 1.72 million restricted shares to the incentive target, of which 1.4 million shares will be awarded for the first time, and a total of 33 people will be granted part of the incentive for the first time.
Corey Technology: the subsidiary plans to acquire Huizhou Dingli Intelligence for 277 million yuan.
Corey Technology (002957) announced on the evening of November 28th that Corey New Energy, a wholly-owned subsidiary of the company, plans to acquire 100% equity of Huizhou Dingli Intelligent Technology Co., Ltd. (referred to as "Dingli Intelligence") in cash, with a transaction price of 277 million yuan. After the completion of the transaction, the company will indirectly hold a 100% stake in Dingli Intelligence. Dingli Intelligence specializes in intelligent testing equipment for charge and discharge of lithium battery, and its products focus on the post-processing process of lithium-ion battery production. The acquisition of Dingli Intelligence will help to complement the company's overall solution capability in the latter part of lithium battery.